- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 风雨不动 于 2012-4-14 15:24 编辑
<http://www.docguide.com/lamivudine-adefovir-has-similar-efficacy-entecavir-issues-renal-and-bone-safety-arise?hash=04301bd4&eid=19348&alrhash=2e06a4-d460252966da8019c5213f6ae197892e>
Source: DGNews | Posted 5 days ago
Lamivudine/Adefovir Has Similar Efficacy to Entecavir, but Issues With
Renal and Bone Safety Arise : Presented at EASL
By Chris Berrie
BERLIN -- April 5, 2011 -- Although de novo combination treatment with
lamivudine plus adefovir (LAM/ADV) achieves similar virological response
rates to entecavir in patients with chronic hepatitis B virus (HBV), the
effects of LAM/ADV indicate problems with long-term renal and bone safety.
Findings were presented here on April 1 at the 46th Annual Meeting of the
European Association of the Study of the Liver (EASL), by Ivana Carey, MD,
King’s College London School of Medicine, and King’s College Hospital,
London, United Kingdom.
For the study, patients with chronic HBV who were naïve to
nucleoside/nucleotide analogue therapy were randomised to combination
LAM/ADV 10 mg/day (n = 192) or entecavir 0.5 mg/day (n = 154), for a median
of 30 months treatment duration.
At 3 months, there were no significant differences in complete virologic
response -- defined as HBV DNA <12 IU/mL -- between patients receiving
LAM/ADV (48%) and those receiving entecavir (54%), nor was there any
significant difference at 30 months (79% and 78%, respectively).
Significantly more patients treated with LAM/ADV than entecavir achieved
hepatitis B e antigen (HBeAg) seroconversion (21% vs 6%; P =.02) and
decreases in HBV DNA from month 24 (P =.05).
There were no differences between groups for viral mutations associated
with drug resistance, serum creatinine levels, or estimated glomerular
filtration rate (eGFR), although eGFR significantly decreased from baseline
to month 18 onwards in the LAM/ADV group (P =.04).
Serum phosphate levels decreased significantly during treatment in the
LAM/ADV group compared with the entecavir group at month 12 (P <.05) and
month 24 (P <.05).
Dr. Carey said that to counterbalance the phosphate loss seen with LAM/ADV
treatment, vitamin D was given to all patients. Alternatively, should
patients already have renal issues, such as diabetes, high blood pressure,
or family history of renal problems, they can be given entecavir rather
than LAM/ADV.
[Presentation title: Long-Term De-Novo Lamivudine + Adefovir Combination
Therapy in Chronic Hepatitis B Is Efficient, but Has Negative Impact on
Renal/ Bone Safety in Comparison to Entecavir Monotherapy. Abstract 707]
(6.合.彩).足球.篮球...各类投注开户下注
第一投注.现金网:招代理年薪10万以上:6668.cc |
|